FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2964704906> ?p ?o ?g. }

• W2964704906 endingPage "607" @default.
• W2964704906 startingPage "607" @default.
• W2964704906 abstract "Introduction: While survival in Hodgkin Lymphoma (HL) is excellent, disparities by race/ethnicity have been described. Population-based and single center studies of children and adolescents with HL suggest that those who are black or Hispanic (vs. non-Hispanic white) have worse outcomes (Grubb Pediatr Blood Cancer 2016; Metzger JCO 2008). Whether race/ethnicity is predictive of survival in children and adolescents with HL after adjusting for clinical features and treatment-related variables is unknown. Our objective was to examine whether race/ethnicity was predictive of event-free survival (EFS), relapse, and overall survival (OS) in patients enrolled on contemporary Children9s Oncology Group (COG) trials with response-based therapy for treatment of newly diagnosed HL. Methods: We conducted a pooled analysis of individual level data in children and adolescents enrolled on 3 consecutive Phase III clinical trials for treatment of intermediate, low and high-risk HL (AHOD0031, AHOD0431, AHOD0831). Five-year EFS and OS were compared across racial/ethnic groups and were estimated using the Kaplan-Meier method. Cumulative incidence of relapse was similarly constructed with K-sample tests. Cox regression models were constructed to examine the influence of race/ethnicity on EFS and OS, and were adjusted for age, sex, insurance status, histology, Ann Arbor stage, B symptoms, bulk disease, COG study, and radiation therapy (RT). Results: Between 2002 and 2012, 2155 patients 1-21 years of age enrolled on 3 COG trials, 2071 (96%) of whom were included in this analysis. Patients treated outside the US and Canada (n=84) were excluded. The distribution of race/ethnicity as reported to COG by treating institutions was: 64% non-Hispanic white (N=1334), 11% non-Hispanic black (N=236), 16% Hispanic (N=329), 3% Asian/Pacific Islander (N=66), and 5% other (N=106). Compared to other groups, more non-Hispanic white patients had private (vs. government) insurance (p Survival: In pooled analysis, with a median follow-up of 6.9 years, 5-year EFS was 83%, OS was 97%, and neither outcome differed by race/ethnicity (EFS: p=0.98; OS: p=0.29). Cumulative incidence of relapse was 16.8% and did not differ by race/ethnicity (p=0.93). In the multivariable model for EFS, there was no significant effect of race/ethnicity (p=0.95). Similarly, race/ethnicity was not significant in the multivariable model for OS (p=0.14). Finally, race/ethnicity was not significantly associated with EFS or OS in multivariable models by individual study, accounting for risk group. Conclusion: We observed no difference in survival by race/ethnicity among children and adolescents treated for HL with contemporary, risk adapted response-based therapy on COG Phase III trials. This suggests that the survival gap observed in population-based studies is largely reduced by access to clinical trials and by receipt of comparable therapy between cohorts. In light of this, it can be hypothesized that inequities in access to high-quality care, rather than differences in individual disease biology may underlie racial disparities observed in the community oncology setting. To examine whether response-based paradigms mitigated biologic differences between groups, further analyses will explore early response to treatment by race/ethnicity. Further analyses will also examine treatment-related toxicities and second malignant neoplasms by race/ethnicity, as well as the independent contribution of socioeconomic status to outcomes. Disclosures No relevant conflicts of interest to declare." @default.
• W2964704906 created "2019-08-13" @default.
• W2964704906 creator A5025395169 @default.
• W2964704906 creator A5029125087 @default.
• W2964704906 creator A5036356438 @default.
• W2964704906 creator A5043738456 @default.
• W2964704906 creator A5054697421 @default.
• W2964704906 creator A5059056112 @default.
• W2964704906 creator A5061910742 @default.
• W2964704906 creator A5073222794 @default.
• W2964704906 creator A5079552409 @default.
• W2964704906 creator A5089358491 @default.
• W2964704906 date "2017-12-07" @default.
• W2964704906 modified "2023-10-03" @default.
• W2964704906 title "Survival By Race/Ethnicity in Children and Adolescents with Hodgkin Lymphoma Treated on Cooperative Group Trials in the U.S. and Canada: A Pooled Analysis of Children's Oncology Group Trials" @default.
• W2964704906 doi "https://doi.org/10.1182/blood.v130.suppl_1.607.607" @default.
• W2964704906 hasPublicationYear "2017" @default.
• W2964704906 type Work @default.
• W2964704906 sameAs 2964704906 @default.
• W2964704906 citedByCount "0" @default.
• W2964704906 crossrefType "journal-article" @default.
• W2964704906 hasAuthorship W2964704906A5025395169 @default.
• W2964704906 hasAuthorship W2964704906A5029125087 @default.
• W2964704906 hasAuthorship W2964704906A5036356438 @default.
• W2964704906 hasAuthorship W2964704906A5043738456 @default.
• W2964704906 hasAuthorship W2964704906A5054697421 @default.
• W2964704906 hasAuthorship W2964704906A5059056112 @default.
• W2964704906 hasAuthorship W2964704906A5061910742 @default.
• W2964704906 hasAuthorship W2964704906A5073222794 @default.
• W2964704906 hasAuthorship W2964704906A5079552409 @default.
• W2964704906 hasAuthorship W2964704906A5089358491 @default.
• W2964704906 hasConcept C120665830 @default.
• W2964704906 hasConcept C121332964 @default.
• W2964704906 hasConcept C121608353 @default.
• W2964704906 hasConcept C126322002 @default.
• W2964704906 hasConcept C137403100 @default.
• W2964704906 hasConcept C143998085 @default.
• W2964704906 hasConcept C144024400 @default.
• W2964704906 hasConcept C149923435 @default.
• W2964704906 hasConcept C154945302 @default.
• W2964704906 hasConcept C19165224 @default.
• W2964704906 hasConcept C207103383 @default.
• W2964704906 hasConcept C2908647359 @default.
• W2964704906 hasConcept C41008148 @default.
• W2964704906 hasConcept C44249647 @default.
• W2964704906 hasConcept C4661277 @default.
• W2964704906 hasConcept C50382708 @default.
• W2964704906 hasConcept C535046627 @default.
• W2964704906 hasConcept C61511704 @default.
• W2964704906 hasConcept C71924100 @default.
• W2964704906 hasConcept C99454951 @default.
• W2964704906 hasConceptScore W2964704906C120665830 @default.
• W2964704906 hasConceptScore W2964704906C121332964 @default.
• W2964704906 hasConceptScore W2964704906C121608353 @default.
• W2964704906 hasConceptScore W2964704906C126322002 @default.
• W2964704906 hasConceptScore W2964704906C137403100 @default.
• W2964704906 hasConceptScore W2964704906C143998085 @default.
• W2964704906 hasConceptScore W2964704906C144024400 @default.
• W2964704906 hasConceptScore W2964704906C149923435 @default.
• W2964704906 hasConceptScore W2964704906C154945302 @default.
• W2964704906 hasConceptScore W2964704906C19165224 @default.
• W2964704906 hasConceptScore W2964704906C207103383 @default.
• W2964704906 hasConceptScore W2964704906C2908647359 @default.
• W2964704906 hasConceptScore W2964704906C41008148 @default.
• W2964704906 hasConceptScore W2964704906C44249647 @default.
• W2964704906 hasConceptScore W2964704906C4661277 @default.
• W2964704906 hasConceptScore W2964704906C50382708 @default.
• W2964704906 hasConceptScore W2964704906C535046627 @default.
• W2964704906 hasConceptScore W2964704906C61511704 @default.
• W2964704906 hasConceptScore W2964704906C71924100 @default.
• W2964704906 hasConceptScore W2964704906C99454951 @default.
• W2964704906 hasLocation W29647049061 @default.
• W2964704906 hasOpenAccess W2964704906 @default.
• W2964704906 hasPrimaryLocation W29647049061 @default.
• W2964704906 hasRelatedWork W1995246501 @default.
• W2964704906 hasRelatedWork W2158683596 @default.
• W2964704906 hasRelatedWork W2465708584 @default.
• W2964704906 hasRelatedWork W2538566363 @default.
• W2964704906 hasRelatedWork W2569582700 @default.
• W2964704906 hasRelatedWork W2587903831 @default.
• W2964704906 hasRelatedWork W2590475133 @default.
• W2964704906 hasRelatedWork W2594644852 @default.
• W2964704906 hasRelatedWork W2626358361 @default.
• W2964704906 hasRelatedWork W2694763134 @default.
• W2964704906 hasRelatedWork W2783393271 @default.
• W2964704906 hasRelatedWork W2794405481 @default.
• W2964704906 hasRelatedWork W2804757345 @default.
• W2964704906 hasRelatedWork W2922440986 @default.
• W2964704906 hasRelatedWork W2926034509 @default.
• W2964704906 hasRelatedWork W2979555779 @default.
• W2964704906 hasRelatedWork W3044598685 @default.
• W2964704906 hasRelatedWork W3089593691 @default.
• W2964704906 hasRelatedWork W3097669108 @default.
• W2964704906 hasRelatedWork W3147098608 @default.
• W2964704906 hasVolume "130" @default.
• W2964704906 isParatext "false" @default.
• W2964704906 isRetracted "false" @default.
• W2964704906 magId "2964704906" @default.

• next